Sepsis - Treatment Report
|発行||Boston Strategic Partners, Inc.||商品コード||557099|
|出版日||ページ情報||英文 68 Pages
In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Real World data report, Hospital-Treated Sepsis: Treatment, estimates 30% of all hospital discharges involve treatment of infectious organisms. Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.
Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.
Hospital-Treated Sepsis: Treatment is part two of a two-part series on hospital-treated sepsis. This report provides quantitative, objective data focused on the treatment of sepsis requiring hospitalization. The data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antimicrobial stewardship.